Across TCGA pan-cancer cohorts, SLC6A9 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC6A9 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC6A9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC6A9 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC and GBM are the cancer types where SLC6A9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	1.000	0.219	.014	14	view →
GBM	OS	Quartile	All	0.955	0.738	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SLC6A9 tumor-vs-normal RNA expression · all SLC6A9 data types